US Patent

US12472172 — Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Method of Use · Assigned to Amryt Pharmaceuticals Inc · Expires 2041-07-29 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating hyperlipidemia or hypercholesterolemia in pediatric patients using lomitapide or a pharmaceutically acceptable salt thereof.

USPTO Abstract

Provided herein are methods of treating hyperlipidemia or hypercholesterolemia in pediatric patients with lomitapide or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

lomitapide-mesylate (LOMITAPIDE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4438`	—	lomitapide-mesylate
`U-4438`	—	lomitapide-mesylate
`U-4438`	—	lomitapide-mesylate
`U-4438`	—	lomitapide-mesylate
`U-4438`	—	lomitapide-mesylate

Patent Metadata

Patent number: US12472172
Jurisdiction: US
Classification: Method of Use
Expires: 2041-07-29
Drug substance claim: No
Drug product claim: No
Assignee: Amryt Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.